These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 8780091)

  • 21. An open trial of controlled release carbidopa/L-dopa (sinemet CR) for the treatment of mild-to-moderate Parkinson's disease.
    Friedman JH; Lannon MC
    Clin Neuropharmacol; 1989 Jun; 12(3):220-3. PubMed ID: 2743346
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Suppression of dyskinesias in advanced Parkinson's disease. I. Continuous intravenous levodopa shifts dose response for production of dyskinesias but not for relief of parkinsonism in patients with advanced Parkinson's disease.
    Schuh LA; Bennett JP
    Neurology; 1993 Aug; 43(8):1545-50. PubMed ID: 8351009
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease.
    Piccini P; Brooks DJ; Korpela K; Pavese N; Karlsson M; Gordin A
    J Neurol Neurosurg Psychiatry; 2000 May; 68(5):589-94. PubMed ID: 10766888
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of etilevodopa compared to levodopa in patients with Parkinson's disease: an open-label, randomized, crossover study.
    Djaldetti R; Giladi N; Hassin-Baer S; Shabtai H; Melamed E
    Clin Neuropharmacol; 2003; 26(6):322-6. PubMed ID: 14646613
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study].
    Chaná P; Fierro A; Reyes-Parada M; Sáez-Briones P
    Rev Med Chil; 2003 Jun; 131(6):623-31. PubMed ID: 12942590
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease.
    LeWitt PA; Huff FJ; Hauser RA; Chen D; Lissin D; Zomorodi K; Cundy KC
    Mov Disord; 2014 Jan; 29(1):75-82. PubMed ID: 24339234
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Controlled-release carbidopa/levodopa in the treatment of Parkinsonism.
    Hutton JT; Dippel RL; Bianchine JR; Strahlendorf HK; Meyer PG
    Clin Neuropharmacol; 1984; 7(2):135-9. PubMed ID: 6375861
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
    Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE
    Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease.
    Müller T; Ander L; Kolf K; Woitalla D; Muhlack S
    J Neural Transm (Vienna); 2007; 114(11):1457-62. PubMed ID: 17564755
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IPX066 , a mixed immediate/sustained-release levodopa preparation for Parkinson's disease.
    Ondo W
    Expert Opin Pharmacother; 2014 Oct; 15(14):2081-5. PubMed ID: 25146967
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial.
    Hauser RA; Hsu A; Kell S; Espay AJ; Sethi K; Stacy M; Ondo W; O'Connell M; Gupta S;
    Lancet Neurol; 2013 Apr; 12(4):346-56. PubMed ID: 23485610
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).
    Stocchi F; Marconi S
    Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics, metabolism and safety of deuterated L-DOPA (SD-1077)/carbidopa compared to L-DOPA/carbidopa following single oral dose administration in healthy subjects.
    Schneider F; Erisson L; Beygi H; Bradbury M; Cohen-Barak O; Grachev ID; Guzy S; Loupe PS; Levi M; McDonald M; Savola JM; Papapetropoulos S; Tracewell WG; Velinova M; Spiegelstein O
    Br J Clin Pharmacol; 2018 Oct; 84(10):2422-2432. PubMed ID: 29959802
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetic-pharmacodynamic interaction between nebicapone, a novel catechol-o-methyltransferase inhibitor, and controlled-release levodopa/carbidopa 200 mg/50 mg : randomized, double-blind, placebo-controlled, crossover study in healthy subjects.
    Vaz-da-Silva M; Loureiro AI; Nunes T; Lopes C; Rocha J; Machado R; Costa R; Torrão L; Falcão A; Wright L; Almeida L; Soares-da-Silva P
    Drugs R D; 2008; 9(6):435-46. PubMed ID: 18989992
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson's disease.
    Verhagen Metman L; Stover N; Chen C; Cowles VE; Sweeney M
    Mov Disord; 2015 Aug; 30(9):1222-8. PubMed ID: 25847690
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson's disease.
    Hutton JT; Morris JL; Bush DF; Smith ME; Liss CL; Reines S
    Neurology; 1989 Nov; 39(11 Suppl 2):67-72; discussion 72-3. PubMed ID: 2685652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and standard Sinemet (25/100).
    Cedarbaum JM; Kutt H; McDowell FH
    Neurology; 1989 Nov; 39(11 Suppl 2):38-44; discussion 59. PubMed ID: 2586762
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of Parkinson's disease with controlled-release Carbidopa/L-DOPA.
    Pahwa R; Koller WC
    Adv Neurol; 1996; 69():487-91. PubMed ID: 8615169
    [No Abstract]   [Full Text] [Related]  

  • 39. Pharmacodynamics, Efficacy, and Safety of IPX203 in Parkinson Disease Patients With Motor Fluctuations.
    Modi NB; Mittur A; Dinh P; Rubens R; Gupta S
    Clin Neuropharmacol; 2019; 42(5):149-156. PubMed ID: 31306216
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Carbidopa/Levodopa ER Capsules (Rytary(®), Numient™): A Review in Parkinson's Disease.
    Greig SL; McKeage K
    CNS Drugs; 2016 Jan; 30(1):79-90. PubMed ID: 26692288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.